# EDGAR Filing Document

**Accession Number:** 0001821586
**File Stem:** 0001140361-26-015917
**Filing Date:** 2026-4
**Character Count:** 5056
**Document Hash:** e149ec4f640a2d371d985549a1229bda
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001140361-26-015917.hdr.sgml**: 20260421

**ACCESSION NUMBER**: 0001140361-26-015917

**CONFORMED SUBMISSION TYPE**: DEFA14A

**PUBLIC DOCUMENT COUNT**: 3

**FILED AS OF DATE**: 20260421

**DATE AS OF CHANGE**: 20260421

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** MoonLake Immunotherapeutics
- **CENTRAL INDEX KEY:** 0001821586
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** E9
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** DEFA14A
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-39630
- **FILM NUMBER:** 26879955

**BUSINESS ADDRESS:**
- **STREET 1:** DORFSTRASSE 29
- **CITY:** ZUG
- **STATE:** V8
- **ZIP:** 6300
- **BUSINESS PHONE:** 41 41 510 8022

**MAIL ADDRESS:**
- **STREET 1:** DORFSTRASSE 29
- **CITY:** ZUG
- **STATE:** V8
- **ZIP:** 6300

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Helix Acquisition Corp
- **DATE OF NAME CHANGE:** 20200818

### UNITED STATES <br>

### SECURITIES AND EXCHANGE COMMISSION <br>

#### Washington, D.C. 20549

### SCHEDULE 14A <br>

#### Proxy Statement Pursuant to Section 14(a) of the <br>

#### Securities Exchange Act of 1934 <br>

#### (Amendment No.)

---

| | |
|:---|:---|
| Filed by the Registrant  | ☒  |
| Filed by a Party other than the Registrant  | ☐ |

---

Check the appropriate box:

☐<br> Preliminary Proxy Statement

☐<br> Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

☐ Definitive Proxy Statement

☒<br> Definitive Additional Materials

☐<br> Soliciting Material under §240.14a-12

---

| |
|:---|
| **MoonLake Immunotherapeutics**  |
| (Name of Registrant as Specified In Its Charter)  |
| (Name of Person(s) Filing Proxy Statement if other than the Registrant) |

---

Payment of Filing Fee (Check all boxes that apply):

☒<br> No fee required.

☐<br> Fee paid previously with preliminary materials.

☐<br> Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11.

------

![](ny20067252x2_defa14aslide1.jpg)

Your Vote Counts! \*Please check the meeting materials for any special requirements for meeting attendance. At the meeting, you will need to request a ballot to vote these shares. Smartphone users Point your camera here and vote without entering a control number For complete information and to vote, visit www.ProxyVote.com Control # V90809-P50459 MOONLAKE IMMUNOTHERAPEUTICS DORFSTRASSE 29 ZUG, SWITZERLAND 6300 MOONLAKE IMMUNOTHERAPEUTICS 2026 Annual General Meeting of Shareholders Vote by June 3, 2026 11:59 PM ET You invested in MOONLAKE IMMUNOTHERAPEUTICS and it's time to vote! You have the right to vote on proposals being presented at the Annual General Meeting of Shareholders. This is an important notice regarding the availability of proxy materials for the shareholder meeting to be held on June 4, 2026. Get informed before you vote View the Notice, Proxy Statement and Annual Report online OR you can receive a free paper or email copy of the material(s) by requesting prior to May 21, 2026. If you would like to request a copy of the material(s) for this and/or future shareholder meetings, you may (1) visit www.ProxyVote.com, (2) call 1-800-579-1639 or (3) send an email to sendmaterial@proxyvote.com. If sending an email, please include your control number (indicated below) in the subject line. Unless requested, you will not otherwise receive a paper or email copy. Vote in Person at the Meeting\* June 4, 2026 8:00 a.m. Eastern Time At the offices of Gibson, Dunn & Crutcher LLP Located at 200 Park Avenue New York, New York 10166

------

![](ny20067252x2_defa14aslide2.jpg)

Vote at www.ProxyVote.com THIS IS NOT A VOTABLE BALLOT This is an overview of the more complete proxy materials that are available to you on the Internet. You may view the proxy materials at www.ProxyVote.com or easily request a paper copy. We encourage you to access and review all of the important information contained in the proxy materials before voting. Please follow the instructions on the reverse side to vote on these important matters. Prefer to receive an email instead? While voting on www.ProxyVote.com, be sure to click "Delivery Settings". V90810-P50459 1. Election of the Class I director nominee to serve until the 2029 Annual General Meeting of Shareholders and until his successor is duly elected and qualified. For Nominee: 1a. Spike Loy 2. Ratification, by ordinary resolution, of the selection of Baker Tilly US, LLP as the Company's independent registered public accounting firm for the year ending December 31, 2026. For 3. Approval of, on a non-binding, advisory basis, the compensation of the Company's named executive officers. For 4. Approval of an amendment and restatement of the Company's 2022 Equity Incentive Plan. For NOTE: Such other business as may properly come before the meeting or any adjournments or postponements thereof. Voting Items Board Recommends

------